Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATEZOGIST: Imatinib + Atezolizumab vs Imatinib Alone in Advanced GIST
NCT05152472Phase 2Active, not recruiting
- Sponsor
- Centre Léon Bérard
- Start
- Jan 2022
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by Centre Léon Bérard. Primary endpoint: Progression-Free Survival at 48 months. Started Jan 2022; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT05152472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05152472.